Scalper1 News
Biotech Achillion Pharmaceuticals (ACHN) announced Tuesday that clinical trials were progressing on its hepatitis C drugs after the FDA lifted a clinical hold, sending shares up 60% in early trading in the stock market today to an eight-month high. The FDA had placed a clinical hold on a phase two trial of drug candidate sovaprevir last July, citing potentially dangerous elevations in the liver enzymes of some patients. Achillion supplied more Scalper1 News
Scalper1 News